FY2025 · ended Dec 31, 2025 · Revenue $800,000, -91.3% YoY · Filed Mar 10, 2026
ImageneBio, Inc. (IMA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $800,000 and a net loss of $45.3 million. As of Jun 30, 2026 it held $136.2 million in cash and investments and $1.9 million in total debt.
Revenue
$800,000
-91.3% vs prior year
Net income
$-45.35M
-24.0% vs prior year
Operating cash flow (TTM)
$-52.59M
-445.3% vs year-ago TTM
Free cash flow
$-80.16M
-6.1% vs prior year
EPS
$-9.64
+56.4% vs prior year
Dividend per share
None
Shares outstanding
48.26M
+0.0% vs prior year
Net cash
$134.24M
as of Jun 30, 2026
Operating margin
-6056.4%
FY 2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1835579
- Former names
- Ikena Oncology, Inc. (until Jul 25, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $800,000 | — | $9.2M | $15.6M | $31.0M |
| Operating income | -$48.5M | -$37.0M | -$75.4M | -$70.9M | -$34.1M |
| Net income | -$45.3M | -$36.6M | -$68.2M | -$68.8M | -$34.1M |
| Diluted EPS | -$9.64 | -$22.10 | -$1.63 | -$1.90 | — |
| Operating cash flow | -$47.8M | -$21.3M | -$79.7M | -$74.1M | -$60.3M |
| Free cash flow | — | — | -$80.2M | -$75.5M | -$62.0M |
| Total assets | $153.0M | $15.9M | $192.1M | $172.3M | $247.9M |
| Total liabilities | $19.8M | $17.4M | $22.3M | $25.3M | $40.0M |
| Stockholders' equity | $133.1M | -$160.6M | -$126.1M | $147.0M | $207.9M |
| Cash and investments | $135.3M | $12.1M | $175.5M | $156.9M | $232.2M |
| Total debt | $3.0M | $7.5M | $10.7M | $5.7M | $7.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Jul 23, 2026 | Jul 20, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 26, 2026 | Jun 22, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 17, 2026 | Jun 16, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 336 ImageneBio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.